| INTRODUCTION
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic idiopathic inflammatory bowel diseases (IBDs) for which no medical cure presently exists. Patients with moderate-to-severe IBD typically require treatment with immunosuppressive medications, and biologic agents are gaining favour due to their efficacy and safety profiles. 1, 2 Hypothesised mechanisms of lack or loss of response to monoclonal antibodies include increased serum clearance and development of immunogenicity, both of which may lead to a decrease in serum concentrations and decrease in clinical response rates. 3 Numerous studies of anti-tumour necrosis factor alpha (anti-TNFα) therapy have documented an association between low serum drug concentrations and low rates of favourable outcomes, such as clinical response, clinical remission and endoscopic mucosal healing. [4] [5] [6] [7] As such, exposureresponse evaluations with measurement of drug concentrations and anti-drug antibody concentrations have been increasingly utilised in an effort to optimise the use of these agents. 3, [8] [9] [10] Vedolizumab is a humanised monoclonal antibody that specifically binds to the α 4 β 7 integrin and blocks lymphocyte interaction with mucosal addressin cell adhesion molecule-1 expressed on the endothelium of mesenteric lymph nodes and gastrointestinal mucosa. 11 As a result, vedolizumab impairs the migration of guthoming lymphocytes into gastrointestinal mucosa and acts via a gutselective mechanism of action. 11 The efficacy of vedolizumab for the treatment of active UC was demonstrated in the large, randomised, controlled trial GEMINI 1. 12 Among patients in GEMINI 1 treated with vedolizumab, 300 mg every 8 weeks (the US Food and Drug Administration [FDA]-approved labelled dosing), a trend towards increasing clinical response at week 52 with increasing vedolizumab concentration quartiles at week 46 was observed. 12 In addition, a post-hoc analysis of GEMINI 1 reported that rates of endoscopic mucosal healing at weeks 6 and 52 improved with increasing vedolizumab concentration quartiles at weeks 6 and 46 respectively. 13 A post-hoc analysis of data from the wider GEMINI clinical trial programme including patients with either UC or CD found that higher vedolizumab concentrations were associated with higher clinical remission rates. 14 Although several small real-world observational studies have evaluated vedolizumab concentrations and clinical outcomes, 15 -18 the studies did not control for the influence of confounding factors on potential associations. Therefore, there is a need for further exploration in an established vedolizumab treatment population such as the participants in the vedolizumab GEMINI trials.
To date, exposure-response studies of biologics in IBD have had two important limitations: (a) they were not designed prospectively with the primary aim of making inferences about the drug exposureresponse relationship; and (b) data were analysed on a population level rather than an individual level, without adjustment for variables that could potentially affect drug clearance and resulting drug concentrations, most notably disease activity/inflammatory burden, serum albumin concentration and body weight. 3, 19 Therefore, studies demonstrating differences in drug concentrations between responders and nonresponders reveal considerable heterogeneity, not only in drug concentration cut-off values predictive of response, but also in drug concentration ranges between responders and nonresponders. 4, 7, [20] [21] [22] [23] [24] Thus, given the limited information on the exposure-response relationship with vedolizumab and the paucity of adjusted exposureresponse data for biologic agents used to treat IBD, the analyses herein aimed to characterise the relationship between vedolizumab exposure and response in UC using patient-level data from GEMINI 1 adjusted for variables known to affect drug clearance and serum concentration. Although methodologies such as quartile analyses and receiver operating characteristic analyses have historically been employed to evaluate the relationship between biologic drug exposure and response, these approaches have the major limitation of not accounting for confounding factors and correlations between endpoints. Consequently, propensity-score-based case-matching was used in the current analysis because one of its unique strengths is the ability to account for confounding factors. Potential vedolizumab concentration targets at important time points during treatment (weeks 6, 14 and steady state) were also proposed. Of note, the data from the week 6 proposed concentration target were generated in part to help design the currently ongoing vedolizumab dose-optimisation randomised controlled trial, ENTERPRET (NCT03029143). An additional aim was to identify whether early vedolizumab concentrations (at weeks 2, 4 and 6) were associated with improved shortterm (at week 14) and long-term (at week 52) clinical outcomes in GEMINI 1.
| METHODS

| Patient population
In the induction phase of GEMINI 1, patients received either doubleblind or open-label vedolizumab 300 mg at weeks 0 and 2. Patients with a clinical response at week 6 were re-randomised 1:1:1 to receive vedolizumab 300 mg every 8 weeks, vedolizumab 300 mg every 4 weeks or placebo, and followed to week 52 ( Figure S1 ). 13 Patients without a response at week 6 received vedolizumab 300 mg every 4 weeks throughout the maintenance phase. Patients treated with placebo during induction continued to receive placebo during maintenance. Ethical guidelines have been previously published for GEMINI 1 (ClinicalTrials.gov number, NCT00783718). 
| Outcome measures
In GEMINI 1, clinical assessments were performed using the com- 
| Vedolizumab concentration measurement
In GEMINI 1, vedolizumab concentrations in serum samples were measured using a direct capture, pharmacokinetic, enzyme-linked immunosorbent assay (ELISA; sandwich), with a lower limit of detection of 0.125 µg/mL. The time points at which these concentrations were drawn were just prior to vedolizumab infusions at weeks 2 and 6 and at the week 4 study visit.
| Covariates and estimation of individual vedolizumab exposures
A number of variables that can potentially affect the clearance of vedolizumab have been identified in a prior population pharmacokinetic analysis and included patient age, weight, history of anti-TNFα treatment, serum albumin concentration and faecal calprotectin concentration. 19 In that analysis, which included approximately 20 000 serum samples from 2000 patients, vedolizumab clearance and serum concentrations were estimated based on multiple vedolizumab studies, including a phase 1 healthy volunteer study, a phase 2 study in UC and the large phase 3 GEMINI 1 and 2 randomised controlled trials (GEMINI 2 showed that vedolizumab was effective as induction and maintenance therapy for active CD). 12, 19, 25, 26 These data led to the development of a full covariate model capable of characterising vedolizumab pharmacokinetics and pharmacodynamics more completely. 19 In the current analysis, the relationship between patientspecific covariates and estimated vedolizumab clearance and vedolizumab concentrations were expressed as P values for the monotonic trend analysis. P values for trends were also explored using the exact Cochran-Armitage trend test.
| Propensity-score case-matching adjustment of the exposure-response relationship
The GEMINI 1 trial lacked a prospectively randomised dose-ranging design, thus creating the potential for an imbalance in observed and unobserved patient-specific covariates that could confound causal inference in the vedolizumab exposure-response relationship. Candidate confounding covariates in the observed data were identified based on the prior multi-study population pharmacokinetic analysis mentioned above. 19 Imbalance in the observed covariates across exposure quartiles was evaluated graphically and with quartile-specific data summaries.
To characterise the vedolizumab exposure-response relationship, a propensity-score-based case-matching analysis was performed, To determine whether early vedolizumab concentrations at weeks 2, 4 and 6 were associated with clinical remission at week 14, the analysis cohort was restricted to GEMINI 1 patients in the intention-to-treat population who were randomised to receive maintenance vedolizumab 300 mg every 8 weeks, as this is the FDA- Thus, the sample size of the antibody-positive population was too small to perform any meaningful analysis.
| RESULTS
| Vedolizumab exposure-response relationship and proposed potential target concentrations
Of the 746 patients who received at least one dose of vedolizumab in GEMINI 1, 693 (93%) had vedolizumab concentrations assessed at week 6 and were included in the exposure-response analysis. Characteristics of these patients are shown in Table 1 . Of note, patients had a mean disease duration of 6.9 years, mean complete Mayo Score of 8.5 and a mean partial Mayo Score of 6.0; 347 (50%) had disease proximal to the splenic flexure, and 281 (41%) had received prior anti-TNFα therapy.
Trends were observed between patient-specific covariates and estimated clearance and concentrations of vedolizumab ( Figure 1 ).
Specifically, history of prior anti-TNFα treatment (P < 0.0001), lower serum albumin concentration (P < 0.0001) and higher faecal calprotectin concentration (P < 0.0001) were each associated with higher estimated vedolizumab clearance quartiles at week 6 and lower estimated vedolizumab concentration quartiles at both week 6 and steady state. Similar but less consistent associations were also observed for patient age (P ≤ 0.0210) and weight (P ≤ 0.0013).
These findings indicated a strong imbalance in the distribution of measured covariates across exposure or clearance quartiles, but it is unknown if similar imbalance existed across other unmeasured factors. For each vedolizumab concentration quartile at week 6 and steady state prior to covariate-based case-matching, the majority of the ASDMs for the patient-specific covariate main effects were >0.1. However, these ASDMs were <0.1 after case-matching, indicating good matching between patients receiving vedolizumab and those receiving placebo.
Given the case-matching-adjusted data, rates of clinical response and remission decreased with increasing estimated vedolizumab clearance quartiles at week 6, whereas these rates rose with increasing estimated vedolizumab concentration quartiles at both week 6 and steady state (P < 0.0001; Figure >18.4 μg/mL at week 14 and >12.7 μg/mL at steady-state trough.
| Association of early vedolizumab concentrations and clinical remission at weeks 14 and 52
To determine the earliest time point at which measurement of vedo- (Table S1 ).
Patients who achieved clinical remission at week 14 showed higher week 4 (P = 0.0328) and week 6 (P = 0.0418) vedolizumab concentrations compared with those who did not achieve remission at week 14; at week 2, vedolizumab concentrations were generally similar between patients who later achieved remission at week 14 and those who did not (P = 0.4592; Figure 4 ). When examining clinical remission status at week 14 by vedolizumab concentration quartiles at weeks 2, 4 and 6, a consistent trend for increasing remission with increasing vedolizumab concentration was observed at week 4 (P = 0.0469) and week 6 (P = 0.0098), but not at week 2 (P = 0.6766; Figure 5 ). At 79.5 P < 0.0001 P < 0.0001 P = 0.0013 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.0050 P = 0.0026 P = 0.0210 P < 0.0001 P < 0.0001 P < 0.0001 F I G U R E 1 Patient-specific covariates (A) weight, (B) age, (C) prior anti-TNFα therapy, (D) serum albumin and (E) faecal calprotectin, stratified by quartiles from low (quartile 1) to high (quartile 4) for estimated concentration and estimated clearance of vedolizumab at week 6 and at steady state. The relationship between patient-specific covariates and estimated vedolizumab clearance and vedolizumab concentrations was expressed as P values for the monotonic trend analysis (A, B, D, E). P values for prior anti-TNFα therapy were determined using the exact Cochran-Armitage trend test (C). TNFα, tumour necrosis factor alpha week 6, a 40% remission rate was reported in the lowest concentration quartile vs 74% in the highest quartile.
Given that it was only at week 6 that vedolizumab concentrations exhibited a consistent association with rates of clinical remission at week 14, the association between clinical remission at week 52 and early vedolizumab concentrations was restricted to week 6, but was expanded to include the entire GEMINI 1 cohort. Clinical remission rates at week 52 increased consistently with increasing quartiles of vedolizumab concentration at week 6, with a 15% remission rate in the lowest concentration quartile and 37% in the highest quartile ( Figure 6 ). respectively. Additionally, when examining early measurements of vedolizumab, unadjusted concentrations at week 6 were consistently associated with short-and long-term clinical remission (at weeks 14 and 52 respectively), implying that the early use of exposure-response data during treatment may provide an opportunity for dose optimisation sooner than week 10, as was previously described. 28 The association between observed vedolizumab concentrations and clinical efficacy is not surprising because similar trends have Estimated vedolizumab clearance (L/day) Quartile 1: Week 6 (0.03 to <0.14); n = 177 Quartile 2: Week 6 (0.14 to <0.18); n = 178 Quartile 3: Week 6 (0.18 to <0.23); n = 177 Quartile 4: Week 6 (0.23 to <0.55); n = 179 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
| DISCUSSION
Clinical response (A) and remission (B) (adjusted for age, weight, history of prior anti-TNFα therapy, serum albumin concentration and faecal calprotectin concentration), stratified by quartiles from low (quartile 1) to high (quartile 4) for estimated concentration and estimated clearance of vedolizumab at week 6 and steady state (n = 170-177). P values were determined using the exact Cochran-Armitage trend test. Clinical response was defined as a reduction in partial Mayo Score of ≥3 points and a ≥30% decrease from baseline, with a decrease of ≥1 point on the rectal bleeding sub-score or an absolute rectal bleeding score ≤1. Clinical remission was defined as a partial Mayo Score of ≤2 points with no individual sub-score >1 point and mucosal healing (endoscopic subscore ≤1). TNFα, tumour necrosis factor alpha OSTERMAN ET AL. . 19 The propensity-score-based case-matching algorithm used in this analysis created well-matched data that allowed analysis of the drug exposureresponse relationship without confounding due to these variables.
Interestingly, the potential vedolizumab concentration target of >37.1 μg/mL at week 6 that we proposed in this analysis to optimise clinical response is very similar to that observed in a recent post-hoc analysis of endoscopic mucosal healing in GEMINI 1. 13 In that study, in which rates of mucosal healing improved with increasing vedolizumab concentration quartiles, the highest vedolizumab concentration quartile at week 6 corresponded to a concentration of >35.7 μg/mL. In contrast, a study by Williet et al reported that vedolizumab trough concentrations of <18.5 µg/mL at week 6 were associated with a need for drug optimisation within 6 months, with an AUROC of 72%. 31 However, that study differed from the present analysis in a number of ways: the Williet et al study was rather small, with only 47 patients in total; two-thirds of the patients in that study had CD, which may be important because the observed vedolizumab dose-response relationship was less consistent in GEMINI 2 (CD) 25 compared with GEMINI 1 (UC) 12 ; and that study did not adjust for factors known to affect vedolizumab clearance.
Nevertheless, the median serum vedolizumab concentration in primary responders was 42.5 µg/mL at week 6 in the Williet et al study, which is similar to the week 6 value of >37.1 μg/mL derived in our analysis. Furthermore, based on the results of our analysis, week 6 appears to be the earliest time point to consider therapeutic drug monitoring with vedolizumab, given the consistent association and statistical trends between vedolizumab concentration quartiles and clinical outcomes.
The strength of the present analysis is that the largest data sets of vedolizumab pharmacokinetic data (derived from the multi-study population pharmacokinetic analysis 19 ) and clinical response data (from GEMINI 1 12 ) were combined to propose potential target vedolizumab concentrations during treatment and to identify the earliest time point at which exposure-response analysis might be beneficial in clinical practice. Additionally, data were taken from randomised controlled trials, which represent the least biased method of data collection currently available.
Although the present analysis is limited by its post-hoc design, it likely provides the most robust insight into vedolizumab exposure- In conclusion, this analysis of the vedolizumab exposure-response relationship used patient-level data from a large data set and adjusted for factors known to affect vedolizumab clearance. Potential target vedolizumab concentrations at weeks 6, 14 and steady state during treatment were proposed to be >37.1, >18.4 and >12.7 µg/mL respectively. Additionally, week 6 was identified as the earliest time point at which vedolizumab concentrations were consistently associated with short-and long-term remission. Until the ongoing ENTERPRET randomised controlled trial is completed, the results of the present analysis provide the most comprehensively adjusted description of the exposure-response relationship for vedolizumab in UC to date.
